Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T16529 |
BEBT-908
PI3Kα inhibitor 1,MDK9521 |
PI3K; HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
BEBT-908 (PI3Kα inhibitor 1) 是一种选择性的PI3Kα抑制剂(IC50<0.1 μM),也抑制 HDAC (0.1 μM≤IC50≤1 μM)。 | |||
T5831 |
Selective PI3Kδ Inhibitor 1
|
PI3K | PI3K/Akt/mTOR signaling |
Selective PI3Kδ Inhibitor 1 是一种 PI3Kδ 抑制剂 (IC50 = 0.9 nM)。 | |||
T9312 |
PI3Kα Inhibitor 7
|
||
PI3Kα Inhibitor 7 是一种有用的有机化合物,可用于生命科学领域的相关研究。其产品编号为 T9312,CAS号为 1239978-63-2。 | |||
T12589 |
PI3Kα/mTOR-IN-1
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
PI3Kα/mTOR-IN-1是一种有效的 PI3Kβ/mTOR 双重抑制剂。在细胞测定中,PI3Kα/mTOR-IN-1的 IC50为7nM,在无细胞测定中 mTOR 和PI3Kβ的Kis 分别为12.5nM 和10.6nM。 | |||
T6510 |
GDC-0349
RG-7603 |
PI3K; mTOR; Autophagy | Autophagy; PI3K/Akt/mTOR signaling |
GDC-0349 (RG-7603) 是一种ATP 竞争性的选择性mTOR 抑制剂,Ki 值为 3.8 nM。它对 PI3Kα 和其他 266 种激酶的抑制作用是 790 倍,可抑制mTORC1和mTORC2复合体。 | |||
T9315 |
2H-Imidazo[4,5-b]pyrazin-2-one, 1,3-dihydro-6-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-
|
Others | Others |
2H-Imidazo[4,5-b]pyrazin-2-one, 1,3-dihydro-6-[6-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]- 是有效的mTOR 抑制剂,对于mTOR 和PI3Kα的IC50分别为0.176 μM 和 >30 μM。 | |||
T14511 |
BAY1082439
N-[8-[[(2R)-2-羟基-3-(吗啉-4-基)丙基]氧基]-7-甲氧基-2,3-二氢咪唑并[1,2-C]喹唑啉-5-基]-2-甲基吡啶-3-甲酰胺 |
Apoptosis; PI3K | Apoptosis; PI3K/Akt/mTOR signaling |
BAY1082439 是一种具有口服活性的,选择性 PI3Kα/β/δ抑制剂。它也能抑制 PIK3CA 的突变形式,它对抑制 Pten 丢失的前列腺癌的生长有很强的作用。 | |||
T8884 |
hSMG-1 inhibitor 11j
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
hSMG-1 inhibitor 11j 是一种嘧啶衍生物,是有效的和选择性的 hSMG-1 抑制剂,IC50 为 0.11 nM。hSMG-1 inhibitor 11j 对 hSMG-1 的选择性是 mTOR (IC50=50 nM),PI3Kα/γ (IC50=92/60 nM) 和 CDK1/CDK2 (IC50=32/7.1 μM) 的 455 倍以上。hSMG-1 inhibitor 11j 可用于癌症研究。 | |||
T36083 |
DS-7423
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
DS-7423 是PI3K 和mTOR 的有效抑制剂,抑制PI3Kα 和 mTOR 的IC50分别为15.6 nM 和 34.9 nM。DS-7423表现出抗癌活性。 | |||
T6730 |
WAY-600
6-(1H-吲哚-5-基)-4-(4-吗啉基)-1-[1-(3-吡啶基甲基)-4-哌啶基]-1H-吡唑并[3,4-D]嘧啶,WAY600 |
VEGFR; PI3K; Src; mTOR | Angiogenesis; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
WAY-600 是一种有效的,选择性的,ATP 竞争型的mTOR 抑制剂,抑制重组 mTOR 酶,其 IC50=9 nM。它能够阻断 mTOR 复合物 1/2 (mTORC1/2) 组装和激活。 | |||
T14214 |
AMG 511
|
PI3K | PI3K/Akt/mTOR signaling |
AMG 511 是一种高效的、口服有效的 I 类 pan-PI3K 抑制剂,对 PI3Kα, β, δ 和 γ 作用的 Ki 值分别为 4 nM, 6 nM, 2 nM 和 1 nM。它它显著抑制了 PI3K 信号,减少 p-Akt (Ser473)。它在小鼠胶质母细胞瘤移植瘤模型中具有抗肿瘤作用。 | |||
T6319 |
OSI-027
ASP4786,OSI027 |
DNA-PK; PI3K; mTOR; Autophagy | Autophagy; DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
OSI-027 (ASP4786) 是一种选择性、可口服和 ATP 竞争性的mTOR 激酶活性抑制剂,IC50为 4 nM。它抑制mTORC1和mTORC2,IC50分别为 22 nM 和 65 nM。 | |||
T11544 | HDACs/mTOR Inhibitor 1 | HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
HDACs/mTOR Inhibitor 1 is a dual HDACs and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies (IC50s: 0.19 nM, 1.8 nM, 1.2 nM, and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα). | |||
T61654 |
PI3Kα-IN-9
|
||
PI3Kα-IN-9 (compound 27) is a highly specific, orally active, and long-lasting inhibitor of PI3Kα, demonstrating potent inhibitory effects with IC50 values of 4.4, 128, 146, and 153 nM against PI3Kα, PI3Kγ, PI3Kδ, and PI3Kβ, respectively. Additionally, PI3Kα-IN-9 exhibits antiproliferative properties and effectively induces apoptosis. Given its characteristics, PI3Kα-IN-9 holds great potential for cancer research [1]. | |||
T35527 |
PI3Kα-IN-4
PI3Kα-IN-4 |
||
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity[1]. PI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC50s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays[1].PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC50s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays[1]. PI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit t... | |||
T35488 |
(S)-PI3Kα-IN-4
(S)-PI3Kα-IN-4 |
||
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC50 of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer[1]. (S)-PI3Kα-IN-4 (compound 11) is a quinazolin-4(3H)-one derivative with 2-substituted-N-methylpropanamide substitution[1]. [1]. Dong J, et, al. Discovery of 3-Quinazolin-4(3 H)-on-3-yl-2, N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitor... | |||
T12460 |
PI3K/mTOR Inhibitor-1
|
PI3K | PI3K/Akt/mTOR signaling |
PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM) | |||
T78211 |
STX-478
|
PI3K | PI3K/Akt/mTOR signaling |
STX-478(化合物 80)为口服活性、能穿透血脑屏障、选择性针对突变型构象PI3Kα的抑制剂。STX-478表现出对肿瘤的强效抑制和长期缩减效果,适用于癌症研究。 | |||
T62438 |
PI3K/mTOR Inhibitor-9
|
||
PI3K/mTOR Inhibitor-9 (Compound 1) 是一种 mTOR 和 PI3K 的有效抑制剂,能够作用于 mTOR (IC50: 38 nM)、PI3Kα (IC50: 6.6 nM)、PI3Kγ (IC50: 6.6 nM) 和 PI3Kδ (IC50: 0.8 nM)。 | |||
T36308 |
PF-06843195
|
||
PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy[1]. PF-06843195 inhibits the breast cancer cell lines MCF7 and T47D proliferation with IC50s of 62 nM and 32 nM, respectively[1].PF-06843195 inhibits pAKT (T308) in MCF7 and T47D cells w... | |||
T74360 |
MEK/PI3K-IN-1
|
||
MEK/PI3K-IN-1(compound 6r)是一种高效的MEK/PI3K抑制剂,IC50值为124 nM(MEK1)、130 nM(PI3Kα)及236 nM(PI3Kδ)。该化合物能够降低pAKT和pERK1/2的活性,并展现对肿瘤细胞的抗增殖作用。 | |||
T79669 |
FD2157
|
Apoptosis | Apoptosis |
FD2157为一种光敏PI3K抑制剂,其对PI3Kα、PI3Kβ、PI3Kγ和PI3Kδ的IC50值分别为43 nM、83 nM、84 nM和14 nM。在365 nm紫外线照射下,该化合物能有效抑制癌细胞增殖,并诱导细胞凋亡(apoptosis)。 | |||
T81264 |
RLY-2608
|
PI3K | PI3K/Akt/mTOR signaling |
RLY-2608为首个靶向PI3Ka的选择性变构抑制剂,具有高度专一性。 | |||
T72374 | PI3K/mTOR Inhibitor-12 | PI3K | PI3K/Akt/mTOR signaling |
PI3K/mTOR Inhibitor-12为口服有效且选择性的PI3K/mTOR抑制剂,对PI3Kα和mTOR的IC50分别为0.06 nM及3.12 nM,表现出抗肿瘤活性且肝毒性较低。 | |||
T10396 |
ATM Inhibitor-1
|
ATM/ATR | DNA Damage/DNA Repair; PI3K/Akt/mTOR signaling |
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibito (IC50: 0.7 nM) anti-tumor activity. It shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM). | |||
T78804 |
PI3Kα-IN-12
|
PI3K | PI3K/Akt/mTOR signaling |
PI3Kα-IN-12(化合物13),作为一种高度选择性的PI3Kα抑制剂,展现出了1.2 nM的IC50值。在HCT-116和U87-MG细胞线上的抑制作用,IC50s分别为0.83 μM和1.25 μM。通过腹腔注射(IP)给予40 mg/kg的PI3Kα-IN-12,能够有效引起接受U87-MG细胞系异种移植的小鼠模型中的肿瘤退缩。 | |||
T79710 |
PI3Kα/HDAC6-IN-1
|
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
PI3Kα/HDAC6-IN-1(化合物21j)是一种针对PI3Kα/HDAC6的双重抑制剂,其IC50值分别为2.9 nM和26 nM。该化合物还能抑制AKT(Ser473)的磷酸化,诱导α-微管蛋白的积累,并促进其乙酰化,但对乙酰化组蛋白H3和H4无显著影响。在L-363细胞系中,PI3Kα/HDAC6-IN-1显示了高效的抑制活性(IC50=0.17 μM),表现出良好的抗癌潜力。 | |||
T81499 | PH14 | PI3K | PI3K/Akt/mTOR signaling |
PH14,作为一种PI3K/HDAC双重抑制剂,对PI3Kα和HDAC3表现出强效抑制能力,其IC50值分别为20.3 nM 和24.5 nM 。该化合物不仅具备抗增殖特性,还能有效诱导Jeko-1细胞走向凋亡,是研究癌症(例如淋巴瘤)的有力工具。 | |||
T14191 |
Alpelisib hydrochloride
BYL-719 hydrochloride |
Others | Others |
Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity[1][2]. Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC50s of 5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, | |||
T81469 | PI3Kα-IN-14 | PI3K | PI3K/Akt/mTOR signaling |
PI3Kα-IN-14(复合物F8)是一款高度选择性的PI3Kα抑制剂,其IC50值为0.14 nM 。此化合物能显著降低线粒体膜的完整性,并在U87-MG细胞中引起G1期细胞周期的停滞以及凋亡现象。此外,PI3Kα-IN-14在不同来源的肿瘤细胞系中均展现出明显的抗增殖能力,其中PC-3的IC50为0.28 μM,HCT-116的IC50为0.57 μM,以及U87-MG的IC50为1.37 μM。 | |||
T79685 | PI3Kα-IN-13 | PI3K | PI3K/Akt/mTOR signaling |
PI3Kα-IN-13(Compound 18a)是一款高效的PI3Kα抑制剂,具有2.5 nM的IC50值。此化合物能够诱发肿瘤细胞的凋亡,并显著抑制癌细胞的增殖,具体IC50值为MCF-7细胞系0.75 μM、HCT-116细胞系3.79 μM、MDA-MB-231细胞系13.71 μM和SW620细胞系9.85 μM。此外,PI3Kα-IN-13能有效阻止肿瘤细胞集落的形成、迁移以及侵袭。 | |||
T79111 | PI3Kγ inhibitor 7 | PI3K | PI3K/Akt/mTOR signaling |
PI3Kγ inhibitor7(compound 2)作为一种有效的PI3Kγ抑制剂,拥有口服活性,并对PI3Kα、PI3Kβ、PI3Kγ、PI3Kδ的抑制作用,其IC50值分别为4768 nM、878.1 nM、3.42 nM、355.2 nM。此外,PI3Kγ inhibitor7还展现出了抗肿瘤活性。 | |||
T74361 | MEK/PI3K-IN-2 | ||
MEK/PI3K-IN-2 (compound 6s) 是一种有效的 MEK/PI3K 抑制剂,其 IC50值分别为 352 nM (MEK1), 107 nM (PI3Kα), 和 137 nM (PI3Kδ)。MEK/PI3K-IN-2 抑制 pAKT 和 pERK1/2 水平。MEK/PI3K-IN-2 对肿瘤细胞具有抗增殖活性。 | |||
T73110 | PI3Ka-IN-5 | ||
PI3Ka-IN-5 是一种有效的PI3Kα/mTOR 抑制剂,IC50值分别为 0.7 nM 和 3.3 nM。PI3Ka-IN-5 可用于结直肠癌的研究。 | |||
T71947 |
SGK1 inhibitor
|
||
SGK1 inhibitor is an inhibitor of serum- and glucocorticoid-regulated kinase 1 (SGK1) and SGK2. It is selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP. SGK1 inhibitor prevents phosphorylation of GSK3β in U2OS cells and decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with the PI3Kα inhibitor BYL719. SGK1 inhibitor reduces tumor growth in an HCC1954 mouse xenograft model when administered in combination with BYL719. | |||
T78691 |
PI3Kδ-IN-12
|
PI3K | PI3K/Akt/mTOR signaling |
PI3Kδ-IN-12(化合物 13)是一款针对PI3Kδ的选择性抑制剂,具有pIC50值为5.8。该化合物对PI3Kδ/γ/β/α的pKi值分别是8.0、6.5、6.4和6.7,适用于慢性呼吸系统疾病如哮喘及慢性阻塞性肺病(COPD)的研究领域。 | |||
T79370 | FD2056 | PI3K | PI3K/Akt/mTOR signaling |
FD2056是一种口服有效的PI3K抑制剂,对PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ的IC50分别为0.30、0.80、1.10、0.42 nM。此外,FD2056对CDK2-CyclinA2和CDK4-CyclinD3的IC50为115.95 nM和2782.15 nM,能够抑制乳腺癌细胞株MDA-MB-231、MDA-MB-468、MCF-7的增殖,其IC50分别为1.06、0.04、1.40 μM,同时诱导(apoptosis)并抑制肿瘤生长。 | |||
T78853 |
PI3K-IN-47
|
PI3K | PI3K/Akt/mTOR signaling |
PI3K-IN-47 (Compound 27) 是一款高度选择性的二价PI3K抑制剂,对PI3Kα具有极低的半抑制浓度(IC50: 0.44 nM), 同时对PI3Kβ、PI3Kγ、PI3Kδ也表现出良好的抑制活性(IC50分别为7.18 nM、13.92 nM、22.83 nM)。此化合物能够有效诱导细胞周期在G1期发生暂停,并且在体外抑制集落形成和细胞迁移。对于HGC-27异种移植的小鼠模型,PI3K-IN-47能够显著抑制肿瘤生长。 |